Severe hypoglycaemia in adults with insulin-treated diabetes: Impact on healthcare resources

Diabetic Medicine

Volumn 33, Issue 4, 2016, Pages 471-477

  Heller, S R ^a   Frier, B M ^b   Herslov M L ^c   Gundgaard, J ^c   Gough, S C L ^d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c NOVO NORDISK A S   (Denmark)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; SITAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG COMBINATION; INSULIN DEGLUDEC, INSULIN ASPART DRUG COMBINATION; LONG ACTING INSULIN;

ADULT; AGE; AMBULANCE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; EMERGENCY WARD; FATALITY; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INJECTION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COST; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG COMBINATION; ECONOMICS; HEALTH CARE COST; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, ORAL; ADULT; CLINICAL TRIALS, PHASE III AS TOPIC; COHORT STUDIES; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN, LONG-ACTING; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SITAGLIPTIN PHOSPHATE;

EID: 84961181818     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12844     Document Type: Article

References (46)

1. Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a cross-sectional survey. Diabet Med 2006; 23: 750-756.
2. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med 2005; 22: 749-755.
3. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50: 1140-1147.
4. Graveling AJ, Frier BM. Impaired awareness of hypoglycaemia: a review. Diabetes Metab 2010; 36(Suppl 3): S64-S74.
5. Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev 2008; 24: 87-92.
6. Harris SB, Khunti K, Landin-Olsson M, Galbo-Jørgensen CB, Bøgelund M, Chubb B et al. Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective. Patient Prefer Adherence 2013; 7: 925-936.
7. MacLeod KM, Hepburn DA, Frier BM. Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 1993; 10: 238-245.
8. Kristensen PL, Hansen LS, Jespersen MJ, Pedersen-Bjergaard U, Beck-Nielsen H, Christiansen JS et al. Insulin analogues and severe hypoglycaemia in type 1 diabetes. Diabetes Res Clin Pract 2012; 96: 17-23.
9. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011; 14: 665-671.
10. Leiter LA, Yale JF, Chiasson JL, Harris SB, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemic management. Can J Diabetes 2005; 29: 186-192.
11. Levy AR, Christensen TL, Johnson JA. Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Qual Life Outcomes 2008; 6: 73.
12. Lundkvist J, Berne C, Bolinder B, Jonsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005; 6: 197-202.
13. Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 2008; 10(Suppl 1): 16-24.
14. Evans M, Khunti K, Mamdani M, Galbo-Jørgensen CB, Gundgaard J, Bøgelund M et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes 2013; 11: 90.
15. Hammer M, Lammert M, Mejias SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009; 12: 281-290.
16. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003; 26: 1176-1180.
17. Dailey GE III. Early insulin: an important therapeutic strategy. Diabetes Care 2005; 28: 220-221.
18. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365: 2002-2012.
19. Geller AI, Shehab N, Lovegrove MC, Kegler SR, Weidenbach KN, Ryan GJ et al. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med 2014; 174: 678-686.
20. Greco D, Pisciotta M, Gambina F, Maggio F. Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older. Exp Clin Endocrinol Diabetes 2010; 118: 215-219.
21. Lipska KJ, Ross JS, Wang Y, Inzucchi SE, Minges K, Karter AJ et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med 2014; 174: 1116-1124.
22. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: guideline for good clinical practice. J Postgrad Med 2001; 47: 199-203.
23. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc 2009; 107: 403-405.
24. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1489-1497.
25. Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013; 98: 1154-1162.
26. Davies MJ, Gross JL, Ono Y, Sasaki T, Bantwal G, Gall MA et al. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab 2014; 16: 922-930.
27. Hirsch IB, Bode B, Courreges JP, Dykiel P, Franek E, Hermansen K et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care 2012; 35: 2174-2181.
28. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1498-1507.
29. Fulcher GR, Christiansen JS, Bantwal G, Polaszewska-Muszynska M, Mersebach H, Andersen TH et al. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care 2014; 37: 2084-2090.
30. Kaneko S, Chow F, Choi DS, Taneda S, Hirao K, Park Y et al. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial. Diabetes Res Clin Pract 2015; 107: 139-147.
31. Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 Units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN Low Volume trial. Diabetes Care 2013; 36: 2536-2542.
32. Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012; 35: 2464-2471.
33. Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Invest 2013; 4: 605-612.
34. Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open label, parallel-group, treat-to-target trial in people with type 2 diabetes. Diabetes Care 2013; 36: 858-864.
35. Philis-Tsimikas A, Del Prato S, Satman I, Bhargava A, Dharmalingam M, Skjøth TV et al. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obes Metab 2013; 15: 760-766.
36. Onishi Y, Ono Y, Rabol R, Endahl L, Nakamura S. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab 2013; 15: 826-832.
37. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-2569.
38. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
39. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
40. Frier BM, Heller S, McCrimmon R eds. Hypoglycaemia in Clinical Diabetes, 3rd ed. Chichester: Wiley-Blackwell, 2014.
41. Heller SR. Hypoglycaemia and diabetes. In Pickup JE, Williams G (Eds), Textbook of Diabetes, 3rd ed. Oxford: Blackwell Science Ltd, 2003; 33.1-33.9.
42. UK National Health Service. UK Tariffs for Admitted Patient Care & Outpatient Procedures - Diabetes with Hypoglycaemia Disorder, 2014. Available at https://www.gov.uk/government/publications/payment-by-results-pbr-operational-guidance-and-tariffs Last accessed June 2014.
43. Lammert M, Hammer M, Frier BM. Management of severe hypoglycaemia: cultural similarities, differences and resource consumption in three European countries. J Med Econ 2009; 12: 269-280.
44. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010; 14: 1-248.
45. Foos V, Grant D, Palmer JL, Varol N, Curtis B, Boye KS et al. Quantifying the direct and indirect costs associated with severe and non-severe hypoglycaemia in subjects with type-2 diabetes who are treated with insulin. Value Health 2013; 16: A436-A437.
46. Harris SB, Leiter LA, Yale JF, Chiasson JL, Kleinstiver P, Sauriol L. Out-of-pocket costs of managing hyperglycemia and hypoglycemia in patients with type 1 diabetes and insulin-treated type 2 diabetes. Can J Diabetes 2007; 31: 25-33.